retatrutide: what the trials say vs what this community says
retatrutide: what the trials say vs what this community says. I have gone back and forth on this for months.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Kept a log specifically because there is so little published. It is one person and it is not data.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation.
injection_site_iris is right about the escalation being the variable. It explains most of the difficult reports here.
injection_site_iris is right about the escalation being the variable.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Which phase 2 arm are you quoting, and at what week?
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
heart rate is the thing people report watching
[removed by moderator]
the TRIUMPH programme is still running, so anything definitive is premature
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
nothing here is available as a prescription product, so read every thread with that in mind
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
small trial, big effect, wide error bars
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
dose escalation in the trials was slow for a reason
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Flair set to Trial Data since the post is about the published readout rather than an experience.
- 1Removed the escalation schedule. There is no published protocol for members…8 comments in this branch · started by u/ledger_mod